18.32 USD
+1.14 (+6.64%)
18.2425 USD
-0.08 (-0.42%)
We assign a fundamental rating of 7 out of 10 to ADMA. ADMA was compared to 533 industry peers in the Biotechnology industry. While ADMA has a great health rating, its profitability is only average at the moment. ADMA is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes ADMA very considerable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year ADMA was profitable.
ADMA had a positive operating cash flow in the past year.
ADMA had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ADMA reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of ADMA (36.83%) is better than 98.87% of its industry peers.
With an excellent Return On Equity value of 48.57%, ADMA belongs to the best of the industry, outperforming 98.69% of the companies in the same industry.
ADMA has a better Return On Invested Capital (25.76%) than 98.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROIC | 25.76% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ADMA (42.87%) is better than 98.31% of its industry peers.
ADMA's Operating Margin of 34.19% is amongst the best of the industry. ADMA outperforms 97.37% of its industry peers.
ADMA has a Gross Margin of 54.71%. This is in the better half of the industry: ADMA outperforms 76.17% of its industry peers.
ADMA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ADMA is creating value.
Compared to 1 year ago, ADMA has more shares outstanding
ADMA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ADMA has been reduced compared to a year ago.
2.2 Solvency
ADMA has an Altman-Z score of 21.12. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
ADMA has a better Altman-Z score (21.12) than 90.43% of its industry peers.
The Debt to FCF ratio of ADMA is 1.78, which is an excellent value as it means it would take ADMA, only 1.78 years of fcf income to pay off all of its debts.
ADMA has a Debt to FCF ratio of 1.78. This is amongst the best in the industry. ADMA outperforms 93.43% of its industry peers.
ADMA has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.16, ADMA is not doing good in the industry: 65.29% of the companies in the same industry are doing better.
Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Altman-Z | 21.12 |
ROIC/WACC2.96
WACC8.69%
2.3 Liquidity
ADMA has a Current Ratio of 7.13. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
ADMA has a Current ratio of 7.13. This is in the better half of the industry: ADMA outperforms 70.92% of its industry peers.
ADMA has a Quick Ratio of 3.65. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
ADMA has a Quick ratio (3.65) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 92.86% over the past year.
Looking at the last year, ADMA shows a very strong growth in Revenue. The Revenue has grown by 27.62%.
The Revenue has been growing by 70.84% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
3.2 Future
Based on estimates for the next years, ADMA will show a very strong growth in Earnings Per Share. The EPS will grow by 32.01% on average per year.
ADMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.94% yearly.
EPS Next Y21.04%
EPS Next 2Y37.55%
EPS Next 3Y35.8%
EPS Next 5Y32.01%
Revenue Next Year19.81%
Revenue Next 2Y22.86%
Revenue Next 3Y24.53%
Revenue Next 5Y20.94%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ADMA is valuated quite expensively with a Price/Earnings ratio of 33.93.
Based on the Price/Earnings ratio, ADMA is valued cheaply inside the industry as 91.56% of the companies are valued more expensively.
ADMA is valuated rather expensively when we compare the Price/Earnings ratio to 25.65, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 19.36, which indicates a rather expensive current valuation of ADMA.
94.00% of the companies in the same industry are more expensive than ADMA, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of ADMA to the average of the S&P500 Index (34.45), we can say ADMA is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.93 | ||
| Fwd PE | 19.36 |
4.2 Price Multiples
92.87% of the companies in the same industry are more expensive than ADMA, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 91.18% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 107.66 | ||
| EV/EBITDA | 25.04 |
4.3 Compensation for Growth
ADMA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ADMA may justify a higher PE ratio.
A more expensive valuation may be justified as ADMA's earnings are expected to grow with 35.80% in the coming years.
PEG (NY)1.61
PEG (5Y)N/A
EPS Next 2Y37.55%
EPS Next 3Y35.8%
5. Dividend
5.1 Amount
No dividends for ADMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
18.32
+1.14 (+6.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners89.29%
Inst Owner Change5.67%
Ins Owners2.35%
Ins Owner Change-0.83%
Market Cap4.37B
Revenue(TTM)488.56M
Net Income(TTM)209.45M
Analysts84
Price Target27.8 (51.75%)
Short Float %7.27%
Short Ratio4.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.96%
Min EPS beat(2)-1.96%
Max EPS beat(2)-1.96%
EPS beat(4)0
Avg EPS beat(4)-10.9%
Min EPS beat(4)-31.17%
Max EPS beat(4)-1.96%
EPS beat(8)3
Avg EPS beat(8)-42.78%
EPS beat(12)6
Avg EPS beat(12)-7.71%
EPS beat(16)8
Avg EPS beat(16)-5.59%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)0.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)2.16%
Revenue beat(8)6
Avg Revenue beat(8)4.26%
Revenue beat(12)10
Avg Revenue beat(12)4.8%
Revenue beat(16)14
Avg Revenue beat(16)6.2%
PT rev (1m)-6.23%
PT rev (3m)-6.23%
EPS NQ rev (1m)5.66%
EPS NQ rev (3m)3.71%
EPS NY rev (1m)4.7%
EPS NY rev (3m)3.64%
Revenue NQ rev (1m)1.4%
Revenue NQ rev (3m)1.84%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.93 | ||
| Fwd PE | 19.36 | ||
| P/S | 8.95 | ||
| P/FCF | 107.66 | ||
| P/OCF | 67.28 | ||
| P/B | 10.14 | ||
| P/tB | 10.23 | ||
| EV/EBITDA | 25.04 |
EPS(TTM)0.54
EY2.95%
EPS(NY)0.95
Fwd EY5.16%
FCF(TTM)0.17
FCFY0.93%
OCF(TTM)0.27
OCFY1.49%
SpS2.05
BVpS1.81
TBVpS1.79
PEG (NY)1.61
PEG (5Y)N/A
Graham Number4.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROCE | 32.61% | ||
| ROIC | 25.76% | ||
| ROICexc | 29.27% | ||
| ROICexgc | 29.53% | ||
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% | ||
| FCFM | 8.31% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Debt/EBITDA | 0.4 | ||
| Cap/Depr | 304.79% | ||
| Cap/Sales | 4.99% | ||
| Interest Coverage | 15.23 | ||
| Cash Conversion | 37.13% | ||
| Profit Quality | 19.39% | ||
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 | ||
| Altman-Z | 21.12 |
F-Score7
WACC8.69%
ROIC/WACC2.96
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y21.04%
EPS Next 2Y37.55%
EPS Next 3Y35.8%
EPS Next 5Y32.01%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
Revenue Next Year19.81%
Revenue Next 2Y22.86%
Revenue Next 3Y24.53%
Revenue Next 5Y20.94%
EBIT growth 1Y45.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.25%
EBIT Next 3Y41.34%
EBIT Next 5Y36.11%
FCF growth 1Y272.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y501.56%
OCF growth 3YN/A
OCF growth 5YN/A
ADMA BIOLOGICS INC / ADMA FAQ
What is the fundamental rating for ADMA stock?
ChartMill assigns a fundamental rating of 7 / 10 to ADMA.
Can you provide the valuation status for ADMA BIOLOGICS INC?
ChartMill assigns a valuation rating of 6 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Fairly Valued.
How profitable is ADMA BIOLOGICS INC (ADMA) stock?
ADMA BIOLOGICS INC (ADMA) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ADMA BIOLOGICS INC (ADMA) stock?
The Price/Earnings (PE) ratio for ADMA BIOLOGICS INC (ADMA) is 33.93 and the Price/Book (PB) ratio is 10.14.
Can you provide the financial health for ADMA stock?
The financial health rating of ADMA BIOLOGICS INC (ADMA) is 8 / 10.